Hirudin — The Primary Anticoagulant
The most potent natural thrombin inhibitor known
Last updated: March 14, 2026
Hirudin is a 65-amino-acid peptide that functions as the most potent natural thrombin inhibitor known to science. This single molecule inspired the development of three FDA-approved anticoagulant drugs and continues to serve as a model for pharmaceutical research.
Molecular Profile
- Size: 65 amino acids, molecular weight ~7 kDa
- Mechanism: Direct thrombin inhibitor with 1:1 stoichiometry
- Potency: Inhibition constant (Ki) ≈ 21 fM (2 × 10⁻¹⁴ M) — one of the tightest protein–protein interactions measured in nature
- Structure: Compact N-terminal domain (residues 1–48) stabilized by 3 disulfide bonds + flexible C-terminal tail (residues 49–65)
- Discovery: First identified by John B. Haycraft (1884); isolated and characterized by Fritz Markwardt (1955)
Mechanism of Action
Hirudin achieves thrombin inhibition through a bivalent binding mechanism — it simultaneously binds:
- Active site of thrombin (N-terminal domain of hirudin, residues 1–48)
- Exosite I (fibrinogen recognition exosite) (C-terminal tail of hirudin, residues 49–65)
This dual-site binding results in complete bivalent inhibition. Unlike heparin-based anticoagulants, hirudin acts directly on thrombin without requiring antithrombin as a cofactor, and it is not neutralized by platelet factor 4 (PF4).
Hirudin vs. heparin
| Property | Hirudin | Heparin (UFH) |
|---|---|---|
| Mechanism | Direct thrombin inhibitor | Indirect (requires antithrombin cofactor) |
| PF4 resistance | Not neutralized by PF4 | Neutralized by PF4 (HIT risk) |
| Clot-bound thrombin | Inhibits clot-bound thrombin | Cannot reach clot-bound thrombin |
| Monitoring | aPTT or ECT | aPTT, anti-Xa |
| Half-life (IV) | ~1–2 hours | ~1–1.5 hours (dose-dependent) |
| Reversal agent | None (no specific antidote) | Protamine sulfate |
| Clearance | Renal (dose adjustment in renal impairment) | Reticuloendothelial + renal |
Isoforms
Different Hirudo species produce distinct hirudin isoforms with slightly varying structures and potencies:
| Isoform | Source | Notes |
|---|---|---|
| HV1 | H. medicinalis | Most extensively studied; template for recombinant drugs |
| HV2 | H. verbana | Slight sequence variation; similar potency |
| HV3 | H. orientalis | Eastern species; distinct pharmacokinetic profile |
Historical timeline
| Year | Event |
|---|---|
| 1884 | John B. Haycraft identifies anticoagulant activity in leech extract |
| 1955 | Fritz Markwardt isolates and characterizes hirudin |
| 1984 | Dodt et al. determine hirudin gene sequence, enabling recombinant production |
| 1998 | Lepirudin (recombinant hirudin) receives FDA approval for HIT |
| 2000 | Bivalirudin (synthetic direct thrombin inhibitor) approved for PCI anticoagulation |
| 2003 | Desirudin approved for DVT prophylaxis |
| 2012 | Lepirudin discontinued (replaced by bivalirudin and argatroban) |
Pharmaceutical Legacy
Hirudin research directly led to the development of three FDA-approved anticoagulant drugs:
| Drug | Type | FDA Approved | Indication | Status |
|---|---|---|---|---|
| Lepirudin (Refludan) | Recombinant hirudin | 1998 | HIT type II | Discontinued 2012 |
| Desirudin (Iprivask) | Recombinant hirudin | 2003 | DVT prophylaxis (hip replacement) | Available |
| Bivalirudin (Angiomax) | Synthetic DTI (hirudin-inspired) | 2000 | Anticoagulation during PCI | Active, widely used |